* A corporate client of Hybridan LLP
** Arranged by type of listing and date of announcement
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced
Dish of the day...
Admissions:
No joiners today.
Delistings:
Dechra Pharmaceuticals has left the Main Market Premium List of the London Stock Exchange.
Potential**** Initial Public Offerings:
12 Jan—The London Tunnels PLC announces its intention to seek admission to the standard segment of the Official List and to trading on the Main Market of London Stock Exchange plc (Admission). The Company plans to restore, adaptively reuse and bring back to life the Kingsway Exchange Tunnels in Central London, originally built in the early 1940s, and designed to shelter people during the London Blitz. The Company has successfully raised approximately £10m from investors and aims to admit its Ordinary Shares at a price of £2.00 per share to the Main Market of the London Stock Exchange. The Company is expected to have a market capitalisation of approximately £123 million on Admission Expected Admission to take place in January 2024.
Reverse Takeovers:
none
Change of Market:
none
Banquet Buffet***
Beowulf Mining 1.3p £15.0m (BEM.L)
Beowulf and its wholly owned Finnish subsidiary Grafintec Oy provide an update for the Graphite Anode Materials Plant (GAMP) in the GigaVaasa area. The strategy is to fast-track full GAMP process to capture more of the anode material production value-chain and provide greater supply-chain security following the export controls imposed by China on graphite materials in December 2023. An enhanced Pre-Feasibility Study (PFS) on the full GAMP process is expected to be concluded during 2024, building on the PFS of the Coating stage of the process previously notified in July 2023 that demonstrated robust economics with a post-tax NPV8 of US$242m and a post-tax IRR of 39%. NPV8 means the NPV calculated based on an eight-year horizon. This enhanced PFS will be followed by a Definitive Feasibility Study during 2025 with first production still planned from 2027.
Bluejay Mining 0.425p £5.1m (JAY.L)
The exploration and development Company with projects in Greenland and Finland announces a capital raise of £1.2m, with a £150k contribution from the Board of Directors. These funds coupled with recent strategic leadership changes allow Bluejay to focus on its assets with momentum. Bluejay remains dedicated to its primary focus, the 2,776 square kilometre Disko-Nuussuaq Magmatic Massive Sulphide nickel-copper-platinum-cobalt project (Disko), located on the west coast of Greenland. The Company has a joint venture with KoBold Metals and is working to agree value enhancing work programmes for 2024.
Blue Star Capital 0.11p £5.5m (BLU.L)
The investing Company with a focus on esports, payments, technology and its applications within media and gaming, announces that it has raised £100k before expenses, pursuant to a placing at a price of 0.1p per share. The proceeds will be used by the Company for working capital purposes and will provide the Company with working capital headroom until September 2024.
Concurrent Technologies 81p £69.4m (CNC.L)
The designer and manufacturer of leading-edge computer products, systems and mission critical solutions used in high-performance markets provides a trading update for the year ending 31 December 2023. The Company expects to report revenues circa 5% ahead of market expectations and profit before tax slightly ahead of market expectations. This makes FY23 a record year, with revenue in excess of £30m compared to £18.3m in FY22. CEO Miles Adcock indicates that the Group is confident that it will increase its share in its addressable market in 2024.
Corero Network Security 8.375p £41.1m (CNS.L)
The provider of real-time, high-performance, automatic Distributed Denial of Service (DDoS) cyber defence solutions provides a trading update for the year ended 31 December 20231. FY23 revenue is expected to be approximately $22.3m, up 11% from the prior year (FY22: $20.1m), adjusted EBITDA is expected to be in the range of $1.9m to $2.3m (FY22: $2.6m), and the cash at 31 December 2023 was $5.2m, with no outstanding debt (net cash 31 December 2022: $4.4m). Annualised Recurring Revenues (ARR) increased to $16.9m as at 1 January 2024, up 17% over the prior year (ARR at 1 January 2023: $14.4m), driven by continued demand for subscription-based and DDoS Protection as-a-service (DDPaaS) products. This strong performance continues to improve earnings visibility and revenue growth in 2024.
Coro Energy* 0.2p £5.7m (CORO.L)
The South East Asian energy Company with a natural gas and clean energy portfolio confirms that further to the Company's announcement of 31 August 2023, the Company has completed its installation of the 130 meter tall meteorological mast in the Philippines. All equipment was delivered to site on time and within budget. The wind data gathering campaign is now underway and will operate for up to twelve months delivering bankable data to the Company's utility scale projects in the province of Oslob.
DSW Capital 57p £12.5m (DSW.L)
The profitable, mid-market, challenger professional services licence network and owner of the Dow Schofield Watts brand announces that Nicole Burstow, Deputy CEO and Chief Financial Officer, has tendered her resignation. Nicole will continue in her role until the end of June 2024, before taking up a new position at a large portfolio investment business. The Company is commencing a recruitment process and will update the market in due course.
MTI Wireless Edge 34p £30.0m (MWE.L)
The technology group focused on comprehensive communication and radio frequency solutions across multiple sectors announces that Mottech Water Solutions Ltd (Mottech), its Water Control & Management division, has successfully retained a key service contract with a local municipality in Israel. Under the contract, Mottech will continue to be responsible for the efficient and cost-effective irrigation of the green land within the municipality. The contract is for a basic term of two years with the potential for extension for up to a further five years, at US$200k per annum, in total worth up to US$1.4m. As the contract is for an existing long-term client, MTI considers it likely that the Company will complete the full seven-year term.
Oxford BioDynamics 27.15p £54.9m (OBD.L)
The biotechnology Company developing precision medicine tests based on the EpiSwitch 3D genomics platform announces its final results for the year ended 30 September 2023. Revenue was £0.51m, up 230% (FY22: £0.15m) and other operating income was £0.83m, up 136% (FY22: £0.35m). The operating loss was £10.2m (FY: £8.6m in loss), primarily due to higher staff cost and admin costs. Cash and term deposits were £5.3m as at 30 September 2023 (FY22: £1.0m). The Company has two precision medicine tests on the market, each with a unique CPT-PLA code in the US. It is now running PSE tests from its own CLIA-registered (Clinical Laboratory Improvement Amendments) clinical operations laboratory in Frederick, MD, with a UK lab scheduled to begin operation by the end of March 2024.
Poolbeg Pharma* 9.05p £45.3m (POLB.L)
The biopharmaceutical Company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need announces promising in vivo results for POLB001 in addressing cancer immunotherapy-induced CRS (Cytokine Release Syndrome). The results, together with the data from the recent LPS (lipopolysaccharide) human challenge trial, further support the Company's strategic expansion of the Phase II ready POLB001 to treat and prevent cancer immunotherapy-induced CRS. The Company believes that POLB001 represents a significant market opportunity estimated at >US$1bn in Multiple Myeloma, High Grade Lymphoma and Acute Lymphoblastic Leukaemia alone.
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.